C2N Diagnostics has partnered with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to explore the connections between neurodegenerative diseases, including Alzheimer’s disease (AD), and neuronal a-synuclein disease (NSD), which covers conditions such as Parkinson’s disease (PD), Lewy body dementia (LBD), and REM behaviour disorder (RBD).

Currently, there is limited data on the prevalence of biomarkers linked to AD and related dementias in the NSD patient group. MJFF is providing over $1.5 million in funding to C2N to support research that connects fluid samples with new biomarker test results, offering insights into how these diseases interact.

The first phase of this collaboration involves MJFF’s Parkinson's Progression Markers Initiative (PPMI), which will use C2N’s PrecivityAD2™ blood test. This test is designed to detect amyloid plaques in the brain, a key feature of AD. Additionally, C2N’s proprietary test for tau protein, specifically for the microtubule binding region (MTBR-tau), will be used. This test is helpful in diagnosing and staging AD by identifying tau tangles, another hallmark of the disease.

Researchers will also examine how biomarkers related to dementia and neurodegeneration change and influence the progression of NSD. The PPMI study, which has been ongoing since 2010, aims to find biomarkers for Parkinson’s disease to speed up progress in diagnosis, treatment, and prevention. This collaboration will apply C2N’s widely recognised biomarker tests, which are already established in Alzheimer’s research, to the PPMI cohort of Parkinson’s samples, helping to advance research and support clinical trials for Parkinson’s disease treatments.

C2N Diagnostics uses advanced liquid-chromatography-tandem mass spectrometry (LC-MS/MS) technology to identify and measure specific proteins in the blood that are crucial to the development of neurological conditions like AD. These tests have been used in over 150 research studies across the globe, further strengthening C2N's role in precision diagnostics for neurological diseases.



Source: c2n.com

Report Abuse